Rilzabrutinib Becomes First FDA-Approved BTK Inhibitor for ITP
Written by
American Journal Managed Care
Published
0
comments
0
min
The FDA has approved rilzabrutinib (Wayrilz; Sanofi) as a groundbreaking treatment for immune thrombocytopenia (ITP), enhancing patient outcomes and quality of life.